Vanda Pharmaceuticals Inc. (VNDA)
After hours:
| Previous Close | 4.4800 |
| Open | 4.5000 |
| Bid | 4.6000 x 500 |
| Ask | 4.6300 x 500 |
| Day's Range | 4.4500 - 4.6250 |
| 52 Week Range | 3.3000 - 7.0000 |
| Volume | |
| Avg. Volume | 2,332,936 |
| Market Cap | 265.823M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | 115.50 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer. Last week, Vanda rejected contract manufacturer Future Pak's offer of $7.25 to $7.75 per share in cash, which represents a 59%-70% premium to Wednesday's closing price, and adopted a shareholder rights plan to avert a hostile takeover attempt. Shareholder Capital, which owns 200,000 outstanding shares of Vanda, asked in its letter, "on what basis did the Board reject Future Pak's offer, which values Vanda shares at nearly 2x their unaffected price."
- Zacks
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
- Zacks
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
